Emergex Vaccines Holding Limited (‘Emergex’), a biotechnology company pioneering a new approach to synthetic vaccine development in the field of infectious diseases, today announces the appointment of Athanasios Papadopoulos, MD, as Chief Medical Officer (CMO), effective 1st March 2019. Dr. Papadopoulos will report directly to Emergex’s CEO Professor Thomas Rademacher.
© EMERGEX VACCINES
Website by Instinctif Partners
Emergex Vaccines Holding Limited (9955881)
4/5 Dunmore Court,
Abingdon, United Kingdom